APA (7th ed.) Citation

Goldberg, S. B., Schalper, K. A., Gettinger, S. N., Mahajan, A., Herbst, R. S., Chiang, A. C., . . . Kluger, Y. (2020). Pembrolizumab for management of patients with NSCLC and brain metastases: Long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncology, 21(5), 655. https://doi.org/10.1016/S1470-2045(20)30111-X

Chicago Style (17th ed.) Citation

Goldberg, Sarah B., et al. "Pembrolizumab for Management of Patients with NSCLC and Brain Metastases: Long-term Results and Biomarker Analysis from a Non-randomised, Open-label, Phase 2 Trial." Lancet Oncology 21, no. 5 (2020): 655. https://doi.org/10.1016/S1470-2045(20)30111-X.

MLA (9th ed.) Citation

Goldberg, Sarah B., et al. "Pembrolizumab for Management of Patients with NSCLC and Brain Metastases: Long-term Results and Biomarker Analysis from a Non-randomised, Open-label, Phase 2 Trial." Lancet Oncology, vol. 21, no. 5, 2020, p. 655, https://doi.org/10.1016/S1470-2045(20)30111-X.